Liver | Lung | Melanoma, skin | Other Female Genital, Phase II
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Volunteers
Health Professionals
What is the purpose of this trial?
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing on CPI treatment, CPI-naïve HCC, and treatment-naïve Endometrial.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrew Dhanasopon, MD, FACS
- Anne Chiang, MD, PhD
- Daniel Boffa, MD
- Emily Duffield, APRN
- Frank Detterbeck, MD, FACS, FCCP
- Frederick Wilson, MD, PhD
- Harriet Kluger, MD
- James Clune, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Justin D. Blasberg, MD, MPH, FACS
- Kathryn Medow, APRN
- Kelly Olino, MD, FACS
- Marianne Davies, NP, DNP, MSN, BSN
- Melissa Gambaccini
- Michael Cecchini, MD
- Michael Hurwitz, MD, PhD
- Pamela L. Kunz, MD
- Roy S. Herbst, MD, PhD
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- Stacey Stein, MD
- Vanna Dest
- Last Updated04/12/2024
- Study HIC#2000027272